Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05925478 · ClinicalTrials.gov registry record · Early Phase 1

Pterygopalatine Fossa Block in Aneurysmal Subarachnoid Hemorrhage

A Early Phase 1 study of Subarachnoid Hemorrhage, Aneurysmal, sponsored by University of Texas Southwestern Medical Center.

Completed
Registry status
Early Phase 1
Development phase
2
Enrollment target
1
Study location

NCT05925478: Completed Early Phase 1 study of Subarachnoid Hemorrhage, Aneurysmal, sponsored by University of Texas Southwestern Medical Center.

NCT05925478 is a Early Phase 1 study of Subarachnoid Hemorrhage, Aneurysmal that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 2 participants, below the 163-participant average among 8 other Subarachnoid Hemorrhage, Aneurysmal trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05925478, a Early Phase 1 study of Subarachnoid Hemorrhage, Aneurysmal, has completed, sponsored by University of Texas Southwestern Medical Center.

COMPLETED
Registry status
Early Phase 1
Development phase
2 participants
Enrollment target
1
Study location

Study Summary

Aneurysmal subarachnoid hemorrhage (aSAH) can cause a severe headache (HA) that is famously treatment-resistant. Current pain regimens are too reliant on opioids, which results in long-term opioid dependence and can obfuscate the neurological examination, which is critical to detect vasospasm and delayed cerebral ischemia. This study will gather the initial evidence of whether the pterygopalatine fossa (PPF) regional anesthesia nerve block can treat aSAH-related HA and reduce opioid consumption in patients with aSAH.

Conditions Studied

Subarachnoid Hemorrhage, Aneurysmal

Interventions

  • PROCEDURE Ptergyopalatine Fossa Block
  • DRUG Bupivacaine 0.25% Injectable Solution

Study Locations (1)

Texas

  • UT Southwestern - Dallas

Trial Details

FieldValue
Enrollment Target 2 participants
Start Date 2023-11-06
Est. Completion 2024-08-20
Phase Early Phase 1
University of Texas Southwestern Medical Center

837 total trials

What the finished NCT05925478 record still lists

NCT05925478 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 163-participant average among 8 other Subarachnoid Hemorrhage, Aneurysmal trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Subarachnoid Hemorrhage, Aneurysmal appearing as the primary indexed condition, and to 2 interventions - of which Ptergyopalatine Fossa Block is the first listed.

NCT05925478 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT05925478 about?

NCT05925478 is a clinical study titled "Pterygopalatine Fossa Block in Aneurysmal Subarachnoid Hemorrhage". Aneurysmal subarachnoid hemorrhage (aSAH) can cause a severe headache (HA) that is famously treatment-resistant. Current pain regimens are too reliant on opioids, which results in long-term opioid dependence and can obfuscate the neurological examination, which is critical to detect vasospasm and de...

What is the current status of trial NCT05925478?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 2 participants. The study started on 2023-11-06. Estimated completion is 2024-08-20.

What conditions does trial NCT05925478 study?

This clinical trial studies the following conditions: Subarachnoid Hemorrhage, Aneurysmal.

What interventions are being tested in trial NCT05925478?

The interventions under investigation include: Ptergyopalatine Fossa Block (PROCEDURE), Bupivacaine 0.25% Injectable Solution (DRUG).

Who is sponsoring clinical trial NCT05925478?

This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05925478 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Subarachnoid Hemorrhage, Aneurysmal

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05925478's enrollment target sits among peer trials

2 9th of 8 the lowest of 8 other Subarachnoid Hemorrhage, Aneurysmal trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Subarachnoid Hemorrhage, Aneurysmal trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05925478, the US trial registry maintained by the National Library of Medicine. NCT05925478 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.